ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Amicus Therapeutics Inc

Amicus Therapeutics Inc (FOLD)

11.78
-0.08
(-0.67%)
Closed March 29 04:00PM
11.78
0.00
(0.00%)
After Hours: 07:21PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
11.78
Bid
11.37
Ask
12.13
Volume
2,475,945
11.485 Day's Range 11.93
9.70 52 Week Range 14.57
Market Cap
Previous Close
11.86
Open
11.87
Last Trade Time
Financial Volume
$ 28,957,056
VWAP
11.6954
Average Volume (3m)
3,143,348
Shares Outstanding
295,382,614
Dividend Yield
-
PE Ratio
-22.90
Earnings Per Share (EPS)
-0.51
Revenue
399.36M
Net Profit
-151.58M

About Amicus Therapeutics Inc

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It... Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Amicus Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FOLD. The last closing price for Amicus Therapeutics was $11.86. Over the last year, Amicus Therapeutics shares have traded in a share price range of $ 9.70 to $ 14.57.

Amicus Therapeutics currently has 295,382,614 shares outstanding. The market capitalization of Amicus Therapeutics is $3.47 billion. Amicus Therapeutics has a price to earnings ratio (PE ratio) of -22.90.

FOLD Latest News

Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">750003/05/2024Cash* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice03/04/2024Date of Plan Adoption or Giving of Instruction, If Relying on Rule...

Form 144 - Report of proposed sale of securities

="/Images/box-unchecked.jpg" alt="Checkbox not checked">1583303/01/2024Cash* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.3-2.4834437086112.0812.2411.32195118411.63280936CS
4-1.37-10.418250950613.1513.59511.32336237612.07962585CS
12-1.82-13.382352941213.614.0911.32314334812.75058737CS
26-0.93-7.3170731707312.7114.579.7304859012.16999997CS
520.65.3667262969611.1814.579.7272219412.27895446CS
1562.1922.83628779989.5914.575.91269549110.89458546CS
260-1.44-10.892586989413.2225.395.91272078611.63728522CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

FOLD Discussion

View Posts
TheFinalCD TheFinalCD 6 months ago
Thoughts on $FOLD here? do u think sales from Pompe disease will turn this one around? There will be little added fixed expenses to sales/workforce. So question will be how much cash flow will Pompe be able to generate... Thoughts are welcome— Ralph (@StuckInStock) September 28, 2023
πŸ‘οΈ0
Triple nickle Triple nickle 6 months ago
Should be 18.00 already
πŸ‘οΈ0
georgie18 georgie18 3 years ago
FOLD ...$9.47...out on the gap up from the $9 range buys...bidding the open gap...will enter again for another trade...:party:
[10:06 AM]
georgie18 β€” 05/24/2021
FOLD...back in at $9.02...:party:
πŸ‘οΈ0
georgie18 georgie18 3 years ago
FOLD...$9.24...in the P/M...:party:
[9:25 AM]
georgie18 β€” Yesterday at 9:41 AM
FOLD...$9.00...took a starter here...:party:
πŸ‘οΈ0
georgie18 georgie18 3 years ago
FOLD...$9.00...took a starter here...:party:
πŸ‘οΈ0
Mygolfballs Mygolfballs 3 years ago
How is this not being talkd about?

Ihub is only penny flippers?

Pffffft
πŸ‘οΈ0
realfast95 realfast95 4 years ago
Sanofi enzyme replacement therapy shows mixed results in Pompe study
Jun. 16, 2020 8:24 AM ET|About: Sanofi (SNY)|By: Douglas W. House, SA News Editor

Sanofi (NASDAQ:SNY) announces positive results from a Phase 3 clinical trial, COMET, evaluating avalglucosidase alfa, an enzyme replacement therapy, in patients with late-onset Pompe disease, an inherited disorder characterized by the buildup of glycogen in the body's cells due to the dysfunction of a certain enzyme.

The study met the primary endpoint demonstrating non-inferiority (no worse than) to alglucosidase alfa (Lumizyme) as measured by the change in respiratory function but it failed to demonstrate superiority, the other primary objective.

Since superiority was not shown, statistical testing of the secondary endpoints was not done.

The safety profiles were comparable.

Development is ongoing.
πŸ‘οΈ0
realfast95 realfast95 4 years ago
CONFIRMED breakout above 13.15, no resistance in area just above.
Type: True breakout from triple resistance.
Target: 14.32,
πŸ‘οΈ0
realfast95 realfast95 4 years ago
Jun-17-20 Initiated BTIG Research Buy $19
πŸ‘οΈ0
realfast95 realfast95 4 years ago
Amicus Therapeutics (FOLD) is seeing some action in the analyst community this week. Yesterday, both JP Morgan and H.C. Wainwright ($20 price target) reissued Buy ratings on this rare disease concern. Today, Citigroup does the same with $15 price target. Here is the commentary from Citi's analyst

The analyst attributes the weakness yesterday in shares of Amicus Therapeutics to Sanofi's (SNY) press release indicating that the company will release Phase 3 data for avalglucosidase alfa at a virtual science session on June 16. This is a key event for Amicus as this neoGAA would compete with its investigational drug AT-GAA, Bansal tells investors in a research note. Given the company issued a press release about hosting such an event, investors are likely putting a high probability to neoGAA's success, hence the weakness in Amicus shares, says the analyst. However, he sees enough differences between the respective Phase 3 programs that it is not easy to compare neoGAA data with AT-GAA on an apples to apples basis. Further, Amicus does not get much credit for AT-GAA in current valuation as fair value of the company is $10 per share on Galafold alone".

https://seekingalpha.com/instablog/498952-bret-jensen/5458158-biotech-analyst-run-down-for-tuesday
πŸ‘οΈ0
Glider549 Glider549 5 years ago
Amicus was able to achieve positive interim results from a phase 1/2 study using AAV-CLN6 gene therapy to treat patients with Batten disease.

Another gene therapy, known as AT-GAA, is currently being explored in a phase 3 study to treat patients with Pompe disease; enrollment completion is expected end of 2019.

The 6-month and 24-month data using AT-GAA to treat patients with Pompe disease are expected to be presented at the World Muscle Society October 1-5, 2019.

Amicus Therapeutics had $575.7 million in cash as of June 30, 2019, with enough cash to fund its operations into 2021.

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $FOLD Video Chart 05-30-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $FOLD Video Chart 03-01-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
stock1ace1 stock1ace1 7 years ago
Not looking so good on news ..


Study Did Not Meet Primary Endpoints

: (
πŸ‘οΈ0
stocktrademan stocktrademan 7 years ago
FOLD buy 12.19

gapped up on FDA speeding up approval process for product
holding gains after recent 18.4M offering at $12.25









normal chart




log chart



πŸ‘οΈ0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4087015-amicus-nda-submission-proves-king-treating-fabry-disease
πŸ‘οΈ0
trendmkr trendmkr 7 years ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Could Be The Force That Brings Change To The FDA https://marketexclusive.com/77970-2/77970/?icd1
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $FOLD Video Chart 03-01-17 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
DorseyE DorseyE 7 years ago
Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///
πŸ‘οΈ0
trendmkr trendmkr 7 years ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Announces The Closure Of Its Senior Convertible Notes http://marketexclusive.com/amicus-therapeutics-inc-nasdaqfold-announces-closure-senior-convertible-notes/50881/?icd1
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $FOLD Video Chart 12-15-16 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
stocktrademan stocktrademan 7 years ago
FOLD bearish 5.81






normal chart




log chart



πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $FOLD Video Chart 11-29-16 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
jones99 jones99 7 years ago
Rare opportunity to add on market overreaction. 10-15% discount is reasonable. 28-30% is easy money. Believe LT FOLD is a mega winner.
πŸ‘οΈ0
thelittleguy thelittleguy 7 years ago
Well there is a huge short position that is feeling the pinch. I only hope that pinch keeps getting tighter and tighter. :)
πŸ‘οΈ0
ClayTrader ClayTrader 7 years ago
* * $FOLD Video Chart 11-07-16 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
FOLD bullish 7.02

nasdaq stocks $1-10 with volume > 100,000




πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
FOLD bullish 6.7821




πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
FOLD bullish 6.595




πŸ‘οΈ0
thelittleguy thelittleguy 8 years ago
I agree. Are physicians going jump on board or take a wait and see approach? You never know until you start seeing the numbers come in. My fingers are crossed and my toes too.
πŸ‘οΈ0
Rolling inflaton Rolling inflaton 8 years ago
I am! Waiting for revenues to start to come in from Europe. That alone can justify the current valuation, but might take a few quarters to get them rolling. Everything else is upside. Let's see what they say in the CC.
πŸ‘οΈ0
thelittleguy thelittleguy 8 years ago
Is no one invested in FOLD but me? Where is everyone?
πŸ‘οΈ0
ClayTrader ClayTrader 8 years ago
* * $FOLD Video Chart 07-27-16 * *

Link to Video - click here to watch the technical chart video
πŸ‘οΈ0
stocktrademan stocktrademan 8 years ago
FOLD bearish 5.87

πŸ‘οΈ0
saziz saziz 8 years ago
$FOLD Detailed setup : http://www.upstockstrading.com/2015/12/upstockstrading-daily-newsletter-26/ should be heading back to $11
πŸ‘οΈ0
Kylef Kylef 8 years ago
Did u Stay in that one for today?

check these out -Add to Watchlist: Apdn,nesv,mine,fzro,awgi from 0.0115, psid from 0.0197, nhmd,rovi, orig from 1.68, kgc
πŸ‘οΈ0
Pennybuster Pennybuster 8 years ago
Sold 75% Plus 1.75. Still Looks Like More Upside Coming Imo.
πŸ‘οΈ0
Pepperchino Pepperchino 8 years ago
I am with you on this call...
πŸ‘οΈ0
Kylef Kylef 8 years ago
I believe this is The beginning of an uptrend.
πŸ‘οΈ0
Pennybuster Pennybuster 8 years ago
$FOLD Nice Bounce Here The Past Few Sessions.
πŸ‘οΈ0
Pennybuster Pennybuster 8 years ago
$FOLD. Great Day Today! Finally The Bounce We Were Looking For.
πŸ‘οΈ0
Pennybuster Pennybuster 8 years ago
$FOLD Still Searching 4 It's Bottom. Added More Today At 6.00.
πŸ‘οΈ0
blindjohn blindjohn 8 years ago
Gonna bounce at open tomorrow imo
πŸ‘οΈ0
perfectpicksfor -you perfectpicksfor -you 8 years ago
Back in at close to the low of the day ,Will we see green again today.
πŸ‘οΈ0
sorkin sorkin 8 years ago
Great call
πŸ‘οΈ0
girlfriend girlfriend 8 years ago
FOLD is not dead money to me…..trade it.
πŸ‘οΈ0
sorkin sorkin 8 years ago
I see a bounce pre market. Fake head, will stay away. $FOLD is dead money at this point.
πŸ‘οΈ0
OB_WEALTH_INC OB_WEALTH_INC 8 years ago
SHORTS GOT SQUEEZED @ 9.30 LOL
πŸ‘οΈ0
OB_WEALTH_INC OB_WEALTH_INC 8 years ago
Lets make $$$$$$$$
πŸ‘οΈ0
girlfriend girlfriend 8 years ago
Fidelity
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock